Oric Pharmaceuticals, Inc. cotiza a 11.81 USD y tiene una capitalización bursátil de $1.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.38 | $-0.34 | $-0.30 |
| Estimado | $-0.38 | $-0.36 | $-0.32 | $-0.37 |
| Sorpresa | — | -5.6% | -6.3% | +18.9% |
| Métrica | ORIC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -33.7% | -40.4% | +6.7% |
| ROA | -31.7% | -32.0% | +0.3% |
| Current Ratio | 14.13 | 2.84 | +11.29 |
| Debt / Equity | — | 0.28 | — |